...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland >The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy
【24h】

The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy

机译：辅助化疗患者生存的影响d治疗直肠癌手术后复发在患者组织学检查节点- a在新辅助化疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Aim The aim of this study was to evaluate whether adjuvant chemotherapy will affect recurrence rate or disease‐free and overall survival in patients with rectal adenocarcinoma who were staged with MRI node‐positive disease (mrN+) preoperatively. These patients underwent neoadjuvant chemoradiotherapy with curative rectal cancer surgery and their pathological staging was negative for nodal disease (ypN0). There is no consensus on the role of adjuvant chemotherapy in such patients. Method Patients who received neoadjuvant chemoradiotherapy and underwent curative rectal cancer surgery for rectal adenocarcinoma staged as [mrTxN+M0] on MRI staging and who on pathological staging were found to be [ypTxN0M0] were retrospectively identified from January 2008 December 2012 from two tertiary referral centres (Royal Marsden Hospital, London and Saint‐Andre Hospital, Bordeaux). Results One hundred and sixty‐three patients were recruited and, after propensity matching at a ratio of 2:1, n? = ? 80 patients were divided to receive adjuvant ( n? = ? 28) or no adjuvant treatment ( n? = ? 52). A comparison of adjuvant chemotherapy vs no adjuvant therapy showed that the mean overall survival was 2.67 vs 3.60?years ( P? = ? 0.42) and disease‐free survival was 2.27 vs 3.32?years ( P? = ? 0.14). Conclusion This study found no significant difference in survival or disease recurrence between patients who received adjuvant chemotherapy and patients who did not. There is no clear evidence to support or dismiss the use of adjuvant chemotherapy for patients who were node positive on preoperative MRI and node negative on histopathological staging. Further multicentre prospective randomized trials are needed to identify the appropriate treatment regime for this group of patients.
机译：摘要本研究的目的是评估目标辅助化疗是否会影响复发率自由和整体或者疾病直肠腺癌患者的生存期他们举行了MRI节点积极应承担的疾病(mrN +)术前。新辅助化疗的疗效直肠癌手术和病理节疾病的分期是负数(ypN0)。没有共识佐剂的作用化疗的病人。收到新辅助化疗和谁治疗直肠癌手术直肠腺癌(mrTxN + M0)在核磁共振分期和病理分期是谁发现[ypTxN0M0]回顾性从2008年1月2012年12月两个三级转诊中心(皇家马斯登医院,伦敦,圣安德烈医院,波尔多)。患者,倾向匹配的比例2:1,n ?都分为接收辅助(n ?没有辅助治疗(n ?辅助化疗与没有辅助治疗表明,意味着总生存期是2.67 vs3.60 ?2.27 vs 3.32是生存?结论本研究没有发现显著的不同生存或疾病复发病人辅助之间化疗病人并没有。没有明确的证据支持或拒绝使用辅助化疗的患者节点积极的术前MRI和节点上-组织病理学分期。多中心前瞻性随机试验需要确定适当的治疗对这组病人政权。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号